Dr. Timos Papagatsias’ Post

Thoughts on this? >> Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #pharmaceutical #healthcare #biotech

🔬 Exciting Breakthrough in Liver Disease Treatment! 🔬 Boehringer Ingelheim's innovative drug, #Survodutide, is making waves in the #pharmaceuticalindustry with its "groundbreaking" results in treating metabolic dysfunction-associated steatohepatitis (#MASH), a severe form of #liverdisease. In a pivotal Phase II trial, a staggering 83% of patients treated with Survodutide showed a significant improvement in their condition, outperforming the #placebo group by a wide margin. This promising GLP-1 receptor dual agonist has not only demonstrated efficacy in MASH treatment but also shown potential in addressing #fibrosis, a common complication of liver diseases. The trial's success paves the way for Survodutide as a leading treatment option for patients with substantial unmet medical needs, offering new hope for those suffering from MASH and fibrosis. MASH, a progressive liver condition linked to #metabolic dysfunctions such as #obesity and insulin resistance, poses a significant health challenge worldwide. Survodutide's dual mechanism targeting both GLP-1 receptors and glucagon receptors may offer a holistic approach to treating this complex disease, emphasizing the importance of innovative treatments in improving patient outcomes. As we await more detailed results from secondary endpoints, the pharmaceutical community is abuzz with the potential impact of Survodutide on liver health and beyond. #boehringeringelheim's commitment to advancing treatment options for interconnected #cardiovascular, #renal, and #metabolic diseases underscores the critical role of research and development in transforming patient care. Stay tuned for more updates on this exciting development in liver disease treatment and join us in celebrating this significant milestone in pharmaceutical innovation. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #BoehringerIngelheim #Survodutide #MASH #liverdisease #GLP1 #fibrosis #pharma #pharmaceutical #pharmaindustry #europe #pharmaceuticalindustry #healthcare

LNP023 (Iptacopan) for Cold Agglutinin Disease: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Novartis Pharmaceuticals #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Biogen needs Leqembi to be successful following discontinuation of Aduhelm, says GlobalData "Biogen focuses on the success of Leqembi after discontinuing Aduhelm. The firm's strategic shift is noteworthy in the healthcare field. Reinforcing its position in the market, it's a pivotal moment for Biogen." #Biogen #Leqembi #HealthcareIndustry #Pharmaceuticals #MarketStrategy #ProductDevelopment #pharma #biotech #pharmiwebcom

Huntington’s Disease Market Forecast 2034: Therapies, Clinical trials, prevalence, Treatment Algorithms by DelveInsight | MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeuti: Huntington’s Disease Market As per DelveInsight, the Huntington’s Disease Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies, research and development and the increase in the incident population of Huntington’s Disease in … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

Thoughts on this? >> Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharmaceutical #pharma

A Future Blockbuster from Arrowhead Pharmaceuticals? Arrowhead's Plozasiran looks poised to become an incredibly effective dyslipidemia treatment, potentially reaching $700M in sales by 2032, according to GlobalData 📊 Targeting the liver protein ApoC3, Plozasiran would fill a crucial gap in the dyslipidemia care market. 🎯 Phase IIb results showed a remarkable 74% reduction in triglyceride levels at 24 weeks, with continued benefits observed at 48 weeks. 📈💡 With Phase III trials underway and FDA Fast Track designation, Plozasiran's approval looks imminent 🌟 #HealthcareInnovation #phaseIIb #biotech #pharmaceuticals #Dyslipidemia #CardiovascularHealth #MedicalBreakthrough #ArrowheadPharmaceuticals 🩺💉

‘Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations’ #pharma #pharmaceutical #pharmaceuticals #lifesciences #science #research #clinicalresearch https://lnkd.in/eXq_nbP7

Milestone Achieved: FDA Greenlights Gilead's Newly Poised “Livdelzi” to Make a Big Impact Perhaps you caught our previous LinkedIn post that was shared by us 2 months ago. As it happens, what we’ve been hoping for has come to fruition. Gilead Sciences has now received FDA approval for Livdelzi (seladelpar), a new treatment for a rare liver disease known as primary biliary cholangitis. This approval is crucial for patients who can’t tolerate or don't respond well to existing treatments. Livdelzi is now available alone or in combination with other therapies and has strong potential in the market. How will Livdelzi's FDA approval reshape the options available for patients with primary biliary cholangitis? RBC Capital Markets analyst Brian Abrahams noted that Livdelzi's "cleaner label and itch relief benefits" are likely to give it a competitive advantage. Feel free to check out the article linked in the comments below.   #Livdelzi #FDAApproval #PrimaryBiliaryCholangitis #GileadSciences #Biotech #Pharma #HealthcareInnovation #LiverDisease #NewTreatment #CymaBayTherapeutics #DrugDevelopment #MarketImpact #MedicalBreakthrough

89bio initiates phase 3 ENLIGHTEN-Cirrhosis trial of pegozafermin in MASH patients with compensated cirrhosis